Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Mimedx (MDXG) Shares Outstanding (2016 - 2026)

Mimedx's Shares Outstanding history spans 16 years, with the latest figure at $148.9 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding rose 0.9% to $148.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $148.9 million, a 0.9% increase, with the full-year FY2025 number at $148.1 million, up 0.79% from a year prior.
  • Shares Outstanding hit $148.9 million in Q1 2026 for Mimedx, up from $148.1 million in the prior quarter.
  • Over the last five years, Shares Outstanding for MDXG hit a ceiling of $148.9 million in Q1 2026 and a floor of $113.5 million in Q1 2022.
  • Historically, Shares Outstanding has averaged $134.0 million across 5 years, with a median of $146.7 million in 2024.
  • Biggest five-year swings in Shares Outstanding: surged 10379.6% in 2022 and later rose 0.05% in 2025.
  • Tracing MDXG's Shares Outstanding over 5 years: stood at $113.7 million in 2022, then grew by 28.6% to $146.2 million in 2023, then grew by 0.48% to $146.9 million in 2024, then rose by 0.79% to $148.1 million in 2025, then increased by 0.57% to $148.9 million in 2026.
  • Business Quant data shows Shares Outstanding for MDXG at $148.9 million in Q1 2026, $148.1 million in Q4 2025, and $148.1 million in Q3 2025.